Literature DB >> 6199588

Prevention of carcinomatosis and bloody malignant ascites in the rat by an inhibitor of angiogenesis.

L S Heuser, S H Taylor, J Folkman.   

Abstract

It has previously been shown that protamine sulfate is an angiogenesis inhibitor. Regional infusion of protamine into the peritoneal cavity is now reported to prevent the growth of intraperitoneal vascularized tumor masses in rats. Walker 256 carcinoma was implanted directly into the liver or into the peritoneal cavity of rats. Hepatic implants grew in the liver with metastases to the wound and mesentery. Injected tumor cells grew as solid tumor masses in the mesentery. Bloody ascites developed after 7 days. Animals received an intraperitoneal infusion of protamine or saline. Protamine significantly inhibited growth of solid tumors in the mesentery (P less than 0.001). Histology showed tumor cells growing only in monolayer but without vascularization. Ascites was not bloody. In saline-treated animals large vascularized tumors grew in the peritoneal cavity and ascites became bloody.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6199588     DOI: 10.1016/0022-4804(84)90094-5

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  8 in total

1.  GM-CSF induces expression of soluble VEGF receptor-1 from human monocytes and inhibits angiogenesis in mice.

Authors:  Tim D Eubank; Ryan Roberts; Michelle Galloway; Yijie Wang; David E Cohn; Clay B Marsh
Journal:  Immunity       Date:  2004-12       Impact factor: 31.745

2.  Antitumor effect of GPA1734 in rat Walker 256 carcinoma.

Authors:  E Missirlis; G Karakiulakis; M E Maragoudakis
Journal:  Invest New Drugs       Date:  1990-05       Impact factor: 3.850

3.  Protamine and mast-cell-mediated angiogenesis in the rat.

Authors:  A Jakobsson; J Sörbo; K Norrby
Journal:  J Exp Pathol (Oxford)       Date:  1990-04

4.  Molecular blockade of VEGFR2 in human epithelial ovarian carcinoma cells.

Authors:  Sirin A I Adham; Ifat Sher; Brenda L Coomber
Journal:  Lab Invest       Date:  2010-03-01       Impact factor: 5.662

5.  Malignant ascites. Clinical and experimental observations.

Authors:  R N Garrison; L D Kaelin; R H Galloway; L S Heuser
Journal:  Ann Surg       Date:  1986-06       Impact factor: 12.969

6.  The use of vascularised spheroids to investigate the action of flavone acetic acid on tumour blood vessels.

Authors:  L J Zwi; B C Baguley; J B Gavin; W R Wilson
Journal:  Br J Cancer       Date:  1990-08       Impact factor: 7.640

7.  Fibroblast recruitment as a tool for ovarian cancer detection and targeted therapy.

Authors:  Roni Oren; Yoseph Addadi; Lian Narunsky Haziza; Hagit Dafni; Ron Rotkopf; Gila Meir; Ami Fishman; Michal Neeman
Journal:  Int J Cancer       Date:  2016-06-20       Impact factor: 7.396

8.  Intrapericardial bevacizumab safely and effectively treats malignant pericardial effusion in advanced cancer patients.

Authors:  Dawei Chen; Yan Zhang; Fang Shi; Hui Zhu; Minghuan Li; Judong Luo; Kaijun Chen; Li Kong; Jinming Yu
Journal:  Oncotarget       Date:  2016-08-09
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.